OncoMatch/Clinical Trials/NCT03198052
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
Is NCT03198052 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for lung cancer.
Treatment: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR — The third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR -CAR-T cell immunotherapy on human cancers will firstly be tested.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Required: GPC3 protein expression
cancer that expresses GPC3 protein
Required: MSLN protein expression
cancer that expresses Mesothelin protein
Required: CLDN18 protein expression
cancer that expresses Claudin18.2 protein
Required: GUCY2C protein expression
cancer that expresses GUCY2C protein
Required: CD276 protein expression
cancer that expresses B7-H3 protein
Required: PSCA protein expression
cancer that expresses PSCA protein
Required: FOLH1 protein expression
cancer that expresses PSMA protein
Required: MUC1 protein expression
cancer that expresses MUC1 protein
Required: TGFB1 protein expression
cancer that expresses TGFβ protein
Required: HER2 (ERBB2) protein expression
cancer that expresses HER2 protein
Required: FUT3 Lewis-Y protein expression
cancer that expresses Lewis-Y protein
Required: AXL protein expression
cancer that expresses AXL protein
Required: EGFR protein expression
cancer that expresses EGFR protein
Demographics
Prior therapy
Cannot have received: gene therapy
Lab requirements
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03198052 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require GPC3?
Yes, GPC3 protein expression is a required biomarker for enrollment.
Does this trial require MSLN?
Yes, MSLN protein expression is a required biomarker for enrollment.
Does this trial require CLDN18?
Yes, CLDN18 protein expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify